Cargando…

Erratum: Pagonabarraga, J.; et al. A Spanish Consensus on the Use of Safinamide for Parkinson’s Disease in Clinical Practice. Brain Sci. 2020, 10, 176

Detalles Bibliográficos
Autores principales:	Pagonabarraga, Javier, Arbelo, José Matías, Grandas, Francisco, Luquin, Maria-Rosario, Martínez Martín, Pablo, Rodriguez-Oroz, Maria Cruz, Valldeoriola, Francesc, Kulisevsky, Jaime
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Erratum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7288153/ https://www.ncbi.nlm.nih.gov/pubmed/32455904 http://dx.doi.org/10.3390/brainsci10050313

Ejemplares similares

A Spanish Consensus on the Use of Safinamide for Parkinson’s Disease in Clinical Practice
por: Pagonabarraga, Javier, et al.
Publicado: (2020)

Safinamide in Clinical Practice: A Spanish Multicenter Cohort Study
por: Martí-Andrés, Gloria, et al.
Publicado: (2019)

Safinamide in the treatment pathway of Parkinson’s Disease: a European Delphi Consensus
por: Stocchi, Fabrizio, et al.
Publicado: (2022)

Impact of Safinamide on Patient-Reported Outcomes in Parkinson’s Disease
por: Espinoza-Vinces, Christian, et al.
Publicado: (2023)

Long-term Efficacy of Safinamide on Parkinson’s Disease Chronic Pain
por: Cattaneo, Carlo, et al.
Publicado: (2018)

A Randomized Clinical Trial to Evaluate the Effects of Safinamide on Apathetic Non-demented Patients With Parkinson's Disease
por: Kulisevsky, Jaime, et al.
Publicado: (2022)

Present and Future of Parkinson’s Disease in Spain: PARKINSON-2030 Delphi Project
por: Santos García, Diego, et al.
Publicado: (2021)

Consensus on the Definition of Advanced Parkinson's Disease: A Neurologists-Based Delphi Study (CEPA Study)
por: Luquin, Maria-Rosario, et al.
Publicado: (2017)

Prevalence of Advanced Parkinson’s Disease in Patients Treated in the Hospitals of the Spanish National Healthcare System: The PARADISE Study
por: Martínez-Castrillo, Juan Carlos, et al.
Publicado: (2021)

The effects of safinamide on dysphagia in Parkinson’s disease
por: Hirano, Makito, et al.
Publicado: (2023)

A European Observational Study to Evaluate the Safety and the Effectiveness of Safinamide in Routine Clinical Practice: The SYNAPSES Trial(1)
por: Abbruzzese, Giovanni, et al.
Publicado: (2021)

Efficacy of Safinamide and Gender Differences During Routine Clinical Practice
por: Pellecchia, Maria T., et al.
Publicado: (2021)

Psychometric Properties of the Apathy Scale in Advanced Parkinson's Disease
por: Wetmore, John B., et al.
Publicado: (2019)

Validation study of the Parkinson’s Fatigue Scale in advanced Parkinson’s disease
por: Martinez-Martin, Pablo, et al.
Publicado: (2019)

Safinamide: an add-on treatment for managing Parkinson’s disease
por: Müller, Thomas
Publicado: (2018)

SURINPARK: Safinamide for Urinary Symptoms in Parkinson’s Disease
por: Gómez-López, Ana, et al.
Publicado: (2021)

Investigational agents in the treatment of Parkinson’s disease: focus on safinamide
por: Malek, Naveed M, et al.
Publicado: (2012)

Adjuvant therapies for Parkinson’s disease: critical evaluation of safinamide
por: Stocchi, Fabrizio, et al.
Publicado: (2016)

Emerging approaches in Parkinson’s disease – adjunctive role of safinamide
por: Müller, Thomas
Publicado: (2016)

Effects of safinamide on pain in patients with fluctuating Parkinson's disease
por: Grigoriou, Sotirios, et al.
Publicado: (2021)

The Current Evidence for the Use of Safinamide for the Treatment of Parkinson's Disease
por: Abbruzzese, Giovanni, et al.
Publicado: (2021)

The effects of safinamide according to gender in Chinese parkinsonian patients
por: Pellecchia, M. T., et al.
Publicado: (2023)

COPPADIS-2015 (COhort of Patients with PArkinson’s DIsease in Spain, 2015), a global –clinical evaluations, serum biomarkers, genetic studies and neuroimaging– prospective, multicenter, non-interventional, long-term study on Parkinson’s disease progression
por: Santos-García, Diego, et al.
Publicado: (2016)

Erratum to: COPPADIS-2015 (COhort of Patients with PArkinson’s DIsease in Spain, 2015), a global –clinical evaluations, serum biomarkers, genetic studies and neuroimaging– prospective, multicenter, non-interventional, long-term study on Parkinson’s disease progression
por: Santos-García, Diego, et al.
Publicado: (2016)

Population pharmacokinetic and pharmacodynamic analyses of safinamide in subjects with Parkinson's disease
por: Loprete, Luca, et al.
Publicado: (2016)

Long-Term Effects of Safinamide on Mood Fluctuations in Parkinson’s Disease
por: Cattaneo, Carlo, et al.
Publicado: (2017)

The Efficacy of Safinamide in the Management of Parkinson's Disease: A Systematic Review
por: Sharaf, Joudi, et al.
Publicado: (2022)

Fatigue in fluctuating Parkinson’s disease patients: possible impact of safinamide
por: Pauletti, Caterina, et al.
Publicado: (2023)

Levodopa Equivalent Dose of Safinamide: A Multicenter, Longitudinal, Case–Control Study
por: Cilia, Roberto, et al.
Publicado: (2023)

Safinamide improves sleep and daytime sleepiness in Parkinson’s disease: results from the SAFINONMOTOR study
por: Santos García, Diego, et al.
Publicado: (2021)

Pain Improvement in Parkinson’s Disease Patients Treated with Safinamide: Results from the SAFINONMOTOR Study
por: Santos García, Diego, et al.
Publicado: (2021)

Corrigendum to “Beneficial effects of fenugreek glycoside supplementation in male subjects during resistance training: A randomized controlled pilot study” [J Sport Health Sci 5 (2016) 176–182]
por: Wankhede, Sachin, et al.
Publicado: (2018)

Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations
por: Borgohain, Rupam, et al.
Publicado: (2014)

Safinamide Improves Non-Motor Symptoms Burden in Parkinson’s Disease: An Open-Label Prospective Study
por: Santos García, Diego, et al.
Publicado: (2021)

Effectiveness of Safinamide over Mood in Parkinson’s Disease Patients: Secondary Analysis of the Open-label Study SAFINONMOTOR
por: Labandeira, Carmen M., et al.
Publicado: (2021)

Subject index for volume 176
Publicado: (1990)

Chimeric Agents Derived from the Functionalized Amino Acid, Lacosamide, and the α-Aminoamide, Safinamide: Evaluation of Their Inhibitory Actions on Voltage-Gated Sodium Channels, and Antiseizure and Antinociception Activities and Comparison with Lacosamide and Safinamide
por: Park, Ki Duk, et al.
Publicado: (2014)

Validation of a simple screening tool for early diagnosis of advanced Parkinson’s disease in daily practice: the CDEPA questionnaire
por: Martinez-Martin, Pablo, et al.
Publicado: (2018)

Depression in the Elderly. Consensus Statement of the Spanish Psychogeriatric Association
por: Agüera-Ortiz, Luis, et al.
Publicado: (2020)

Effects of Safinamide on Pain in Fluctuating Parkinson’s Disease Patients: A Post-Hoc Analysis
por: Cattaneo, Carlo, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_62vupo20ujq9jc1d7ro0cihgo7